Genetic patent on cancer mouse faces opposition
The coalition of 25 animal welfare groups from 12 European countries yesterday launched a campaign to oppose the first European patent on a living animal. Harvard University was granted a provisional patent by the European Patent Office (EPO) in May last year for its 'Oncomouse' - a creature genetically engineered to contract cancer.
Yesterday, one month before the deadline for opposing the decision, the animal welfare groups submitted detailed legal arguments to the EPO that, because the European Patent Convention expressly prohibits any action that would be 'contrary to morality', the mouse could not be patented.
The patent is sweeping and would apply to dogs, rabbits or chimpanzees whose genes had similarly been manipulated. The coalition argues that 'the public would not readily accept the morality of genetically engineering a primate or a dog so that it should develop cancer'.
Joyce D'Silva, director of Compassion in World Farming, one of the British groups leading the campaign, warned that patent applications are pending for farm animals, including a transgenic chicken given the gene which produces growth hormone in cattle. Such chickens would grow faster and produce leaner meat.
Ms D'Silva said that legislation had created a 'duty of care' for all animal owners - no one legally can be deliberately cruel to an animal. However, the EPO's decision 'has enshrined a new form of animal ownership which carries no duty of care', she said. Instead, the Oncomouse was created in order to suffer.
The opposition groups also question just how well the EPO has assessed the usefulness of the patent. They argue that, increasingly, scientists are conducting cancer research using cells cultured in the laboratory and that to promote animal research would be a retrograde step.
In addition they say the patent is irreligious: humanity cannot claim to have 'invented' an animal; it is God who creates life.
Professor Sir David Weatherall, professor of clinical medicine at Oxford University, has already criticised the Oncomouse patent. In the textbook The New Genetics and Clinical Practice he warns that the public may reject the benefits of the new techniques.
- 1 Howard Jacobson: Let's see the 'criticism' of Israel for what it really is
- 2 Instagram of US airport security chiefs: Lipstick knives and IED training kits among items seized
- 4 PornHub begs users to stop uploading video clips of Brazil getting beaten 7-1
Sustained immigration has not harmed Britons' employment, say government advisers
Australia facing international condemnation after turning around Sri Lankans at sea
7/7 memorial defaced on anniversary of 2005 attacks with ‘Blair lied thousands died’ graffiti
Even when it brutalises one of its own teenage citizens, America is helpless against Israel
There’s a nasty smell in the political air – and it’s coming from the Tories
Vanessa Feltz criticises 'vile' reaction to Rolf Harris allegations
£60000 - £75000 per annum: Harrington Starr: Business Analyst Consultant (Fina...
£60000 per annum: Harrington Starr: A leading provider in investment managemen...
£600 - £700 per day: Harrington Starr: AVS, JVS Openlink Endur Developer JVS, ...
£45000 - £60000 per annum + competitive: Progressive Recruitment: Exciting opp...